17 results about "Systemic inflammatory response syndrome" patented technology

The present invention relates to the early treatment, including pre-diagnosis treatment, of sepsis and acute inflammatory syndromes such as systemic inflammatory response syndrome (SIRS) by PLA2 and metalloprotease inhibitors to improve the performance of antibiotics and outcomes prior to and after confirmation of the diagnosis of sepsis and / or SIRS in a patient or subject. Additional embodiments include methods of treating sepsis, anthrax and severe acute respiratory syndrome coronavirus (SARS and SARS-CoV2) and related inflammatory syndromes and compositions, including pharmaceutical compositions and blood sample compositions. In further embodiments, the present invention is directed to embodiments which evidence that LY315920, LY333013 and related sPLA2 inhibitors are particularly effective COVID-19 / cytokine release syndrome therapeutics-prophylactics. In embodiments, the PLA2 inhibitor is varespladib (LY315920), methyl varespladib (LY333013), AZD2716-(R)-3-(5′-benzyl-2′-carbamoyl-[1,1′-biphenyl]-3-yl)-2-methylpropanoic acid—as a racemic mixture or separately, as the “R” enantiomer), compound 4 (3-(5′-benzyl-2′-carbamoyl-[1,1′-biphenyl]-3-yl)-propanoic acid) and LY433771 ((9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl) oxyacetic acid), a pharmaceutically acceptable salt thereof or a mixture thereof. In embodiments, the metalloprotease inhibitor is Prinomastat, Batimastat, marimastat or vorinostat dosed alone or in combination with preferred sPLA2 inhibitors for the treatment of infection, inflammatory and wound conditions arising from various causes. Methods and compositions for achieving accelerated treatment of wounds and burns, anthrax metalloprotease toxin (lethal factor) driven complications, ARDS, neo-natal and pediatric acute respiratory distress syndrome (neo-natal / pediatric ARDS), including meconium aspiration syndrome and other disease states and conditions are also disclosed.

The invention discloses application of 1, 5-anhydro-D-sorbitol (1, 5-anhydroglaucitol, called 1, 5-AG for short) in inhibition of activation of NLRP3 inflammasomes, and particularly discloses application of 1, 5-anhydro-D-sorbitol (1, 5-AG for short) in inhibition of activation of NLRP3 inflammasomes. The invention relates to an application of 1, 5-anhydro-D-sorbitol in preparation of a medicine for inhibiting activation of NLRP3 inflammasomes, in particular to an application of 1, 5-anhydro-D-sorbitol. The NLRP3 inflammasome activation related diseases are selected from septicaemia induced by LPS, gouty arthritis induced by MSU, non-alcoholic fatty liver disease, systemic inflammatory response syndrome or inflammatory bowel disease. The 1, 5-AG is combined with an NATCH structural domain of the NLRP3 protein, so that the interaction between the 1, 5-AG and NEK7 and ASC is inhibited. The invention relates to an application of 1, 5-anhydro-D-sorbitol in preparation of functional food for inhibiting activation of NLRP3 inflammasomes. The 1, 5-AG is natural in source, high in oral bioavailability and high in safety, and has the advantage of being further developed into inflammation regulation drugs or dietary supplements.

The present disclosure provides methods of developing a test to determine if an infection is present or absent, methods for developing a test to determine the etiology of an infection, methods of using tests to determine presence of an infection, such as infections related to sepsis, versus a non-infectious disease / disorder, such as systemic inflammatory response syndrome (SIRS), and methods of using tests to determine the etiology of an infection. Also provided are systems and computer-implemented methods of developing and using tests as set forth herein.

The present invention relates to the use of albumin for regulating immune cells in subjects requiring it. In particular, the present invention relates to compositions comprising human albumin for use in regulating immune cells in subjects having systemic inflammatory response syndromes.

Disclosed are method and apparatus for identifying biomarkers and in particular for identifying biomarkers for use in making clinical assessments, such as early diagnostic, diagnostic, disease stage, disease severity, disease subtype, response to therapy or prognostic assessments. In one particular example, the techniques are applied to allow assessments of patients suffering from, suspected of suffering from, or with clinical signs of SIRS (Systemic Inflammatory Response Syndrome) being either infection-negative SIRS or infection-positive SIRS.

This invention belongs to the pharmaceutical field and relates to an elastase inhibitor and its application in disease treatment. Specifically, it relates to a compound of formula (I), a pharmaceutical composition comprising compound (I), and its application in disease treatment. The compound of formula (I) of this invention has an inhibitory effect on elastase and can be used to treat or prevent diseases caused by the action of elastase, including systemic inflammatory response syndrome (SIRS) with acute lung injury (ALI) / acute respiratory distress syndrome (ARDS).

The present invention relates to the use of albumin for modulating immune cells in a subject in need thereof. In particular, the present invention relates to a composition comprising human albumin for use in modulating immune cells in a subject suffering from systemic inflammatory response syndrome.

A compound of formula (I) or a salt thereof are provided:wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

The invention discloses a phase separation mediated nano trap for removing extracellular free DNA (Deoxyribonucleic Acid) as well as a preparation method and application thereof, and relates to the technical field of medical nano biological materials. The nano trap takes hollow mesoporous cerium dioxide as a core, DNA degrading enzyme is loaded in the nano trap through a coordinate bond, and a cationic polymer layer is modified on the surface of the nano trap, so that the nano trap has positive zeta potential. The structure can be used as a nucleation center to efficiently capture negatively charged cfDNA; the cfDNA is mediated to generate liquid-liquid phase separation to form a stable aggregate, and then the cfDNA is subjected to in-situ degradation through a loaded enzyme. The invention further discloses a construction method of the nano trap and application of the nano trap in preparation of drugs for treating or preventing systemic inflammatory response syndromes (such as septicopyemia) mediated by abnormal cfDNA level rise. The nano trap provided by the invention has the advantages of high cfDNA removal efficiency, innovative mechanism, synergistic effects of oxidation resistance and bacteria resistance and the like, and provides an effective new way for treatment of related diseases.

The application belongs to the technical field of biological medicine, and particularly relates to application of (E)-BCI hydrochloride in preparation of a medicine for treating sepsis. The application provides application of (E)-BCI hydrochloride in preparation of the medicine for treating sepsis. (E)-BCI hydrochloride regulates a DRD1 gene through targeting, quiets an interferon stimulation storm, reduces abnormal activation of astrocytes, reduces a level of an inflammatory factor, improves expression of a nerve activity gene, and provides a non-antibiotic dependent medicine for sepsis treatment from a new target point of regulating inflammation and immune balance, and is particularly suitable for systemic inflammatory response syndrome caused by various causes such as infection, operation and trauma, and has a wide clinical application prospect.

A method for preventing and / or treating systemic inflammatory response syndrome (SIRS), the method comprising administration of an agent capable of up-regulating CD73 in combination with a glucocorticoid and / or an agent capable of agonizing the glucocorticoid receptor, wherein an agent capable of up-regulating CD73 and a glucocorticoid and / or an agent capable of agonizing the glucocorticoid receptor are administered sequentially. An agent capable of up-regulating CD73 is administered prior to a glucocorticoid and / or an agent capable of agonizing the glucocorticoid receptor.

Provided herein are compositions and methods related to the treatment of acute pancreatitis (AP) in subjects having accompanying Systemic Inflammatory Response Syndrome (SIRS). The present disclosure provides a method for treating AP including administering a therapeutically effective amount of an intracellular calcium signaling inhibitor to a subject, wherein said subject optionally has accompanying systemic inflammatory response syndrome (SIRS).

To provide an in vitro method for assessing the risk of developing sepsis, systemic inflammatory response syndrome (SIRS), septic shock, or multiple organ dysfunction syndrome (MODS) in a subject. Also provided are pharmaceutical compositions for the treatment of sepsis, SIRS, septic shock or MODS in a subject.SOLUTION: Determining or having determined the presence or absence of i) a PCSK9 variant nucleic acid sequence encoding a Pro-protein convertase subtilisin / kexin type 9 (Arg46Leu) PCSK9; and ii) a low-density-lipoprotein receptor (LDLR) variant nucleic acid sequence comprising a single nucleotide polymorphism rs6511720 in a biological sample obtained from the subject, wherein the subject is a PCSK9 reference and being a LDLR reference indicates that the subject has an increased risk of developing SIRS / MODS.SELECTED DRAWING: None

To provide a pharmaceutical composition for use in the treatment of a disease selected from sepsis, secondary hemophagocytic lymphohistiocytosis, cytokine release syndrome, and systemic inflammatory response syndrome in a mammal in need thereof.SOLUTION: Provided is a pharmaceutical composition comprising a BTK inhibitor that is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.SELECTED DRAWING: None

The disclosure relates to in vivo and ex vivo uses of dihydronicotinamide riboside (NRH), dihydronicotinic acid riboside (NARH) and reduced derivatives thereof to treat immune-related disorders (e.g., systemic inflammatory response syndrome and sepsis), kidney disorders (e.g., acute kidney injury and hepatorenal syndrome [HRS]), liver disorders (e.g., acute liver failure and HRS), hemolytic disorders (e.g., hemolysis and hemolytic anemia), and disorders and conditions associated with oxidative stress, damage or injury (e.g., methemoglobinemia and anemia). NRH, NARH and reduced derivatives thereof can be used in vivo or ex vivo alone or in combination with one or more additional therapeutic agents, such as an anti-inflammatory agent or / and an antioxidant.

Disclosed are method and apparatus for identifying biomarkers and in particular for identifying biomarkers for use in making clinical assessments, such as early diagnostic, diagnostic, disease stage, disease severity, disease subtype, response to therapy or prognostic assessments. In one particular example, the techniques are applied to allow assessments of patients suffering from, suspected of suffering from, or with clinical signs of SIRS (Systemic Inflammatory Response Syndrome) being either infection-negative SIRS or infection-positive SIRS.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine compound preparation for nourishing and activating yang and a preparation method and application thereof. The traditional Chinese medicine compound preparation for nourishing and activating yang is prepared from the following raw materials in parts by weight: 5-30 parts of notopterygium root, 5-30 parts of cassia twig, 5-30 parts of honey-fried licorice root, 15-50 parts of ginger, 5-30 parts of ligusticum wallichii, 5-30 parts of radix saposhnikoviae, 5-20 parts of scutellaria baicalensis, 5-30 parts of radix paeoniae alba, 5-30 parts of ginseng, 5-20 parts of prepared radix aconiti carmichaeli, 10-40 parts of white mulberry root-bark, 5-30 parts of angelica sinensis, 5-30 parts of moutan bark, 10-40 parts of radix rehmanniae recen and 8-30 parts of poria cocos. The traditional Chinese medicine compound preparation for nourishing and activating yang, provided by the invention, is used as a medicine for treating or improving systemic inflammatory response syndromes, strengthens the body resistance to eliminate pathogenic factors through multiple effects of dispelling wind and relieving exterior syndrome, warming channels and expelling cold, promoting blood circulation to remove blood stasis, clearing heat and drying dampness, tonifying qi and spleen, warming yang and expelling cold, nourishing yin and clearing heat and the like, harmonizes yin and yang, dredges qi and blood and improves clinical symptoms of patients; the traditional Chinese medicine composition reduces the inflammatory factor level, regulates the immune function, reduces the occurrence of complications, improves the survival rate and life quality of patients, and is safe and reliable.